|
期刊名称：JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
|
Welcome to the new Journal of Clinical Psychopharmacology website. Over the coming months we will be adding new features and services to improve your online experience. We are also upgrading our infrastructure to provide improved reliability and availability to our customers worldwide. As a result of this upgrade we are requiring previously registered users of this site to complete a one-time re-registration step.
Journal Description - This leading publication in psychopharmacology offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.
ISSN: 0271-0749
Online ISSN: 1533-712X
Frequency: Six issues per year
Editor
Richard I. Shader M.D.
David J. Greenblatt M.D. |
Instructions to Authors
Scope: The Journal of Clinical Psychopharmacology is intended for practicing clinicians and trainees interested in improving their knowledge and in keeping up with the changing world of clinical psychopharmacology. The scope of the Journal includes clinical trials and studies, side effects and other undesired reactions, drug interactions, overdosage management, pharmacogenetics, pharmacokinetics, and the psychiatric effects of nonpsychiatric drugs. Problems of special populations (the elderly, children, adolescents, pregnant women, and minorities) are of particular concern.
Clinicians and researchers are invited to submit their findings and observations to the following sections: Original Contributions (clinically relevant investigations, and animal work with direct applicability to clinical care questions), Brief Reports (condensed research findings), and Letters to the Editors. Authors who wish to submit review articles should first contact the EDITORS.
Manuscript Submission: A submitted manuscript must be an original contribution not previously published (except as an abstract or preliminary report), must not be under consideration for publication elsewhere, and, if accepted, must not be published elsewhere in similar form, in any language, without the consent of Lippincott Williams & Wilkins. Each person listed as an author is expected to have participated in the study to a significant extent. Although the editors and referees make every effort to ensure the validity of published manuscripts, the final responsibility rests with the authors, not with the Journal, its editors, or the publisher.
Patient anonymity and informed consent: It is the author's responsibility to ensure that a patient's anonymity be carefully protected and to verify that any experimental investigation with human subjects reported in the manuscript was performed with informed consent and following all the guidelines for experimental investigation with human subjects required by the institution(s) with which all the authors are affiliated. Authors should mask patients' eyes and remove patients' names from figures unless they obtain written consent from the patients and submit written consent with the manuscript.
Copyright: All authors must sign a copy of the journal's Copyright Transfer Form after the manuscript is accepted.
Permissions: Authors must submit written permission from the copyright owner (usually the publisher) to use direct quotations, tables, or illustrations that have appeared in copyrighted form elsewhere, along with complete details about the source. The author must also obtain written permission (which will be kept in the permanent files of the Editors-in-Chief) from persons shown in photographs. Any permissions fees that might be required by the copyright owner are the responsibility of the authors requesting use of the borrowed material, not the responsibility of Lippincott Williams & Wilkins.
General format: Submit a total of four copies of the manuscripts in English (one original and two copies) and printed on standard 81/2 x 11-inch (21 x 28-cm) paper with at least a 1-inch (2.5 cm) margin on all sides. Double space all copy, including legends, footnotes, tables, and references, and print on one side of the sheet only. If a manuscript is accepted for publication, the authors must then submit the final, accepted version of the manuscript on disk.
Title page: Include on the title page (a) complete manuscript title; (b) authors' full names, highest academic degrees, and affiliations; (c) name and address for correspondence, including fax number, telephone number, and e-mail address; (d) address for reprints if different from that of corresponding author; (e) sources of support that require acknowledgment; and (f) a running title of no more than 4 words.
Unstructured abstract and key words: Limit the abstract to 250 words. It must be factual and comprehensive. Limit the use of abbreviations and acronyms, and avoid general statements (eg, "the significance of the results is discussed"). Abstracts should be submitted on a separate page with Original Contributions and Brief Reports. List three to six key words or phrases.
Text: Organize the manuscript into four main headings: Introduction, Materials and Methods, Results, and Discussion. Define abbreviations at first mention in text and in each table and figure. If a brand name is cited, supply the manufacturer's name and address (city and state/country). Acknowledge all forms of support, including pharmaceutical and industry support, in an Acknowledgments paragraph.
Abbreviations: For a list of standard abbreviations, consult the Council of Biology Editors Style Guide (available from the Council of Science Editors, 9650 Rockville Pike, Bethesda, MD 20814) or other standard sources. Write out the full term for each abbreviation at its first use unless it is a standard unit of measure.
References: The authors are responsible for the accuracy of the references. Key the references (double-spaced) at the end of the manuscript. Cite the references in numerical order in the text, indicated by superscripts, and list them in the same order in the reference list at the end of the manuscript. Citations in text to editions of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III, DSM-III-R, or DSM-IV) are acceptable, but it is not necessary to list the DSM in the references. Cite unpublished data, such as papers submitted but not yet accepted for publication or personal communications, in parentheses in the text. If there are more than three authors, name only the first three authors and then use et al. Refer to the List of Journals Indexed in Index Medicus for abbreviations of journal names, or access the list at http://www.nlm.nih.gov/tsd/serials/lji.html. Sample references are given below:
Journal article
1. Greenblatt DJ, Shader RI, Koch-Weser J. Flurazepam hydrochloride, a benzodiazepine hypnotic. Ann Intern Med 1975;83:237-41.
Book chapter
1. Greenblatt DJ, Shader RI. Bad trips. In: Shader RI, ed. Manual of psychiatric therapeutics. Boston: Little, Brown and Co., 1975:203-10.
Entire book
1. Shader RI, ed. Manual of psychiatric therapeutics. Boston: Little, Brown and Co., 1975.
Software
1. Epi Info [computer program]. Version 6. Atlanta: Centers for Disease Control and Prevention, 1994.
Online journals
1. Falkner B, Sherif K, Michel S, et al. Dietary nutrients and blood pressure in urban minority adolescents at risk for hypertension. Arch Pediatr Adolesc Med [serial online]. 2000;154:918-22. Available at: http://archpedi.ama-assn.org/issues/current/abs/poa90542. html. Accessed October 6, 2000.
Database
1. CANCERNET-PDQ [database online]. Bethesda, MD: National Cancer Institute, 1996. Updated March 29, 1996.
World Wide Web
1. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS web site]. June 1, 1996. Available at: http://www.ama-assn.org/special/hiv/. Accessed June 26, 1997.
Figures: Cite figures consecutively in the text, and number them in the order in which they are discussed. Write the first author's last name, the figure number and figure part (1A, 1B, 1C), and an arrow to indicate the top edge of the figure on a label pasted to the back of each figure. Submit all artwork in camera-ready form; illustrations should be glossy prints or high-quality, laser-printed illustrations. Photocopies are unacceptable. Lettering should be large enough that it will remain legible after figure reduction; typewritten or unprofessional lettering is unacceptable. Figure parts (A, B, C) may be left unlabeled (but clearly marked on back) for professional placement by the Journal's printer.
Figure legends: Legends must be submitted for all figures. They should be brief and specific, and they should appear on a separate manuscript page after the references. Use scale markers in the image for electron micrographs, and indicate the type of stain used.
Color figures: The journal accepts for publication color figures that will enhance an article. Authors who submit color figures will receive an estimate of the cost for color reproduction. If they decide not to pay for color reproduction, they can request that the figures be converted to black and white at no charge.
Digital figures: Electronic art should be created/scanned and saved and submitted as either a TIFF (tagged image file format), an EPS (encapsulated postscript) file, or a PPT (Power Point) file. Line art must have a resolution of at least 1200 dpi (dots per inch), and electronic photographs—radiographs, CT scans, and so on—and scanned images must have a resolution of at least 300 dpi. If fonts are used in the artwork, they must be converted to paths or outlines or they must be embedded in the files. Color images must be created/scanned and saved and submitted as CMYK files. All electronic art must be accompanied by high-resolution laser prints of the images. Files can be submitted on a 3?inch high-density disk, a CD-ROM, or an Iomega Zip disk. Please note that artwork generated from office suite programs such Corel Draw and MS Word and artwork downloaded from the Internet (JPEG or GIFF files) cannot be used.
Tables: Cite tables consecutively in the text, and number them in that order. Key each on a separate sheet, and include the table title, appropriate column heads, and explanatory legends (including definitions of any abbreviations used). Do not embed tables within the body of the manuscript. They should be self-explanatory and should supplement, rather than duplicate, the material in the text.
Style: Pattern manuscript style after the American Medical Association Manual of Style (9th edition). Stedman's Medical Dictionary (27th edition) and Merriam Webster's Collegiate Dictionary (10th edition) should be used as standard references. Refer to drugs and therapeutic agents by their accepted generic or chemical names, and do not abbreviate them. Use code numbers only when a generic name is not yet available. In that case, supply the chemical name and a figure giving the chemical structure of the drug. Capitalize the trade names of drugs and place them in parentheses after the generic names. To comply with trademark law, include the name and location (city and state in USA; city and country outside USA) of the manufacturer of any drug, supply, or equipment mentioned in the manuscript. Use the metric system to express units of measure and degrees Celsius to express temperatures, and use SI units rather than conventional units.
Informed Consent: Manuscripts reporting experimental drug investigations on human subjects must contain a statement that subjects (or parents/guardians) gave their consent to participate after procedures and possible side effects were explained to them. If this was not written consent, reason(s) must be given.
Original Studies: The Journal requires authors to affirm that all original studies submitted for publication have been carried out in accordance with Declaration of Helsinki and/or with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health.
Address for manuscript submission: Send the manuscript with a cover letter that includes the corresponding author's e-mail address to:
Richard I. Shader, MD
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY?
Tufts University School of Medicine
Department of Pharmacology and Experimental Therapeutics
136 Harrison Ave., Boston, MA 02111
(Please see the checklist at the end of these Instructions before mailing manuscripts). For information, call (617) 636-2178; e-mail: barbara.kern@tufts.edu. The editorial office will acknowledge receipt of your manuscript and will give you a manuscript number for reference. Address all inquiries regarding manuscripts not yet accepted or published to the Journal's editorial office.
After Acceptance
Disk submission: Authors must submit an electronic version of the final accepted manuscript along with a printout of the final accepted manuscript. Electronic files should be submitted in a standard word processing format; Microsoft Word (or Corel WordPerfect) is preferred. Although conversions can be made from other word processing formats, the vagaries of the conversion process may introduce errors. Do not submit ASCII text files. Do not use automatic numbering or footnotes for references. The Journal does not assume responsibility for errors in the conversion of customized software, newly released software, and special characters. Authors preparing manuscripts on Macintosh computers should not use the Fast Save option. Each submitted disk must be clearly labeled with the name of the author, item title, journal title, word processing program and version, and file name used. The disk should contain only one file the final version of the accepted manuscript.
Page proofs and corrections: Corresponding authors will receive electronic page proofs to check the copyedited and typeset article before publication. Portable document format (PDF) files of the typeset pages and support documents (eg, reprint order form) will be sent to the corresponding author by e-mail. Complete instructions will be provided with the e-mail for downloading and printing the files and for faxing the corrected page proofs to the publisher. Those authors without an e-mail address will receive traditional page proofs. It is the author's responsibility to ensure that there are no errors in the proofs. Changes that have been made to conform to journal style will stand if they do not alter the authors' meaning. Only the most critical changes to the accuracy of the content will be made. Changes that are stylistic or are a reworking of previously accepted material will be disallowed. The publisher reserves the right to deny any changes that do not affect the accuracy of the content. Authors may be charged for alterations to the proofs beyond those required to correct errors or to answer queries. Proofs must be checked carefully and corrections faxed within 24 to 48 hours of receipt, as requested in the cover letter accompanying the page proofs.
Reprints: Authors will receive a reprint order form with the page proofs that includes reprint costs. Reprint requests should be returned with the corrected proofs, if possible. Reprints are normally shipped 6 to 8 weeks after publication of the issue in which the item appears. Contact the Reprint Department, Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436, with any questions.
Publisher's contact: Send corrected page proofs, reprint order forms, color proofs, and any other related materials to:
Journal Production Editor
Journal of Clinical Psychopharmacology
Lippincott Williams & Wilkins
350 Walnut Street
Philadelphia, PA 19106
Manuscript Checklist (before submission) To top of page
- Four copies of complete manuscript with clearly labeled figures
- Cover letter
- Title page
- Abstract
- References double-spaced in AMA style
- Corresponding author designated (in cover letter and on title page)
- Permission to reproduce copyrighted materials or signed patient consent forms
- Acknowledgments listed for grants and technical support
- Disk and high-quality print of electronic art
- Disk containing final version of manuscript after acceptance by editorial office
Editorial Board
This leading publication in psychopharmacology offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.
| |
|
| |
Business Correspondence
Publisher
Maria M. McMichael
E-mail: mmcmicha@lww.com
Account Manager
David Saltzberg
E-mail: dsaltzbe@lww.com
Marketing Manager
Genevieve Alexander
E-mail: galexand@lww.com
Business Offices
Lippincott Williams & Wilkins
530 Walnut Street
Philadelphia, PA 19016
Phone: 215-521-8300
http://www.lww.com
|
|
Editorial Correspondence
Editor-in-Chief
Richard I. Shader, MD
Journal of Clinical Psychopharmacology
Tufts University School of Medicine
Dept of Pharmacology and Experimental Therapeutics
136 Harrison Ave.
Boston, MA 02111
Phone:(617) 636-2178
E-mail: barbara.kern@tufts.edu
|
|
|
|
|
